triazinate
Term · Oncology and biomedicine · MLC-T-ONC-017315
A synthetic dihydrotriazine derivative with antineoplastic properties. As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis. Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells.
| Identifier | MLC-T-ONC-017315 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | BAF |
| Synonyms | Baker's antifol; ethanesulfonic acid compound; Baker's Antifolate; Bakers antifolate; soluble Baker's antifol |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017315",
"term": "triazinate",
"field": "Oncology and biomedicine",
"definition": "A synthetic dihydrotriazine derivative with antineoplastic properties. As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis. Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells.",
"abbreviation": "BAF",
"synonyms": [
"Baker's antifol",
"ethanesulfonic acid compound",
"Baker's Antifolate",
"Bakers antifolate",
"soluble Baker's antifol"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/triazinate/"
}
Record 16,702 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.